SCHEMBL5469448

SCHEMBL5469448

CCOc1cccc(-c2cnc(Nc3ccc(N4CCN(C)CC4)cc3)o2)c1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 5/20 0.55
VCP P55072 3/20 0.53
MAPKAPK2 P49137 1/20 0.47
JAK2 O60674 1/20 0.45
KDR P35968 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
IMPDH2 P12268 1/20 0.44
AURKA O14965 1/20 0.43
CDK4 P11802 1/20 0.43
MAP4K1 Q92918 2/20 0.43
DGAT1 O75907 1/20 0.43
FLT1 P17948 1/20 0.43
FLT4 P35916 1/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5184581 0.92 VCP (0.52) BRD4VCPMAPKAPK2JAK2KDR
SCHEMBL5472158 0.90 VCP (0.67) BRD4VCPMAPKAPK2JAK2KDR
SCHEMBL5464712 0.90 VCP (0.51) BRD4VCPMAPKAPK2JAK2KDR
SCHEMBL16349075 0.89 VCP (0.53) BRD4VCPKDRMEN1KMT2A
SCHEMBL5477362 0.89 MAPT (0.55) BRD4VCPMAPKAPK2KDRKMT2A
SCHEMBL5465435 0.88 VCP (0.52) BRD4VCPMAPKAPK2JAK2KDR
SCHEMBL5472810 0.87 BRD4 (0.56) BRD4VCPMAPKAPK2JAK2KDR
SCHEMBL5475253 0.85 VCP (0.50) BRD4VCPMAPKAPK2JAK2KDR
SCHEMBL5235804 0.84 VCP (0.49) BRD4VCPMAPKAPK2JAK2KDR
SCHEMBL5186408 0.84 VCP (0.61) VCPMAPKAPK2KDRMAP4K1FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189712-B2 1,3-Oxazole compounds for the treatment of cancer SMITHKLINE BEECHAM CORPORATION (US) 2007-03-13 US claimed
US-20050288515-A1 Chemical compounds SMITHLINE BEECHAM CORPORATION 2005-12-29 US claimed
US-20070142437-A1 CHEMICAL COMPOUNDS BROWN MATTHEW L 2007-06-21 US disclosed
US-20070142437-A1 CHEMICAL COMPOUNDS BROWN MATTHEW L 2007-06-21 US disclosed
US-7189712-B2 1,3-Oxazole compounds for the treatment of cancer SMITHKLINE BEECHAM CORPORATION (US) 2007-03-13 US disclosed
US-7189712-B2 1,3-Oxazole compounds for the treatment of cancer SMITHKLINE BEECHAM CORPORATION (US) 2007-03-13 US disclosed
US-20050288515-A1 Chemical compounds SMITHLINE BEECHAM CORPORATION 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142437-A1 CHEMICAL COMPOUNDS CDK4, CDK2, CDK3 BRD4 201/4885VCP 3873/4885MAPKAPK2 269/4885
US-20050288515-A1 Chemical compounds CDK4, CDK2, CDK3 BRD4 201/4885VCP 3873/4885MAPKAPK2 269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.